Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday. They currently have a $37.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 8.57% from the company’s current price.
BOLD has been the subject of a number of other research reports. Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Raymond James Financial assumed coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating for the company. ValuEngine cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. William Blair assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Audentes Therapeutics currently has an average rating of “Buy” and a consensus target price of $35.00.
Audentes Therapeutics (NASDAQ:BOLD) traded down $0.02 during trading on Wednesday, hitting $34.08. 249,967 shares of the stock traded hands, compared to its average volume of 602,233. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $41.80. The stock has a market cap of $1,157.84, a PE ratio of -9.77 and a beta of 0.41.
In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 18,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,000 shares of company stock valued at $1,052,480 in the last ninety days. 47.30% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC lifted its holdings in Audentes Therapeutics by 27.1% during the 2nd quarter. ProShare Advisors LLC now owns 15,581 shares of the biotechnology company’s stock worth $298,000 after buying an additional 3,324 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Audentes Therapeutics during the 3rd quarter worth approximately $143,000. Nationwide Fund Advisors lifted its holdings in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Audentes Therapeutics by 86.1% during the 3rd quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock worth $404,000 after buying an additional 6,667 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in Audentes Therapeutics during the 4th quarter worth approximately $208,000. Institutional investors own 64.76% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Audentes Therapeutics (BOLD) Earns Buy Rating from HC Wainwright” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/07/audentes-therapeutics-bold-earns-buy-rating-from-hc-wainwright.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.